{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:04:57Z","timestamp":1771927497975,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer (BC) management in China faces significant challenges, particularly in terms of standardizing diagnosis and treatment protocols across various healthcare settings. The implementation of a quality control (QC) indicator system offers a potential solution to improve treatment consistency and outcomes. This study evaluated the impact of a QC indicator system on the standardization of neoadjuvant and adjuvant therapies for BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A QC system was developed by an expert panel in alignment with China\u2019s 2022 guidelines. A comparative study was conducted between Jiangsu Cancer Hospital (experimental, implementing PDCA-cycle management) and Nantong Tumor Hospital (control, routine practices). Key indicators included cTNM staging completeness, chemotherapy record standardization, and rational anti-tumor drug use. Additionally, clinical outcomes, patient-reported outcomes (PROs), and treatment adherence were assessed, alongside qualitative data derived from clinical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After the QC system was implemented, Jiangsu Cancer Hospital demonstrated significant improvements: cTNM staging completeness increased from 92.5% to 98.08%, chemotherapy record standardization improved by 66.65%, and rational drug use rose from 78% to 87.5% (all P&amp;lt;0.05). In contrast, no significant improvements were observed in the control hospital. The clinical outcomes and patient-reported symptoms also demonstrated favorable trends in the intervention hospital. Qualitative data revealed facilitators such as clearer treatment protocols and improved coordination, while challenges included increased documentation workload.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The QC system effectively enhanced the standardization of neoadjuvant and adjuvant therapies for breast cancer, with improvements in clinical management and rational drug use. These results offer a scalable model for improving breast cancer management quality in other regions and institutions. Further research, including multi-center studies with extended follow-up, is recommended to validate these findings and explore the long-term impact of QC interventions on patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1597546","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:25:36Z","timestamp":1769491536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of quality control indicator system management program on neoadjuvant and adjuvant therapies for breast cancer: a comparative analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Silu","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nianyang","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sainan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meixin","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nantong Tumor Hospital\/Affiliated Tumor Hospital of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijuan","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nantong Tumor Hospital\/Affiliated Tumor Hospital of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Information Office, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengzheng","family":"Xie","sequence":"additional","affiliation":[{"name":"Beijing Shijitan Hospital Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panqi","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinwei","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nantong Tumor Hospital\/Affiliated Tumor Hospital of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nantong Tumor Hospital\/Affiliated Tumor Hospital of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B3","unstructured":"The healthy China 2030 Strategic Plan\n          \n          \n          \n          2016"},{"key":"B4","unstructured":"Opinions of the State Council on the Implementation of the healthy China Initiative\n          \n          \n          \n          2019"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20220104-00008","article-title":"Quality control index for standardized diagnosis and treatment of breast cancer in China (2022 Edition)","volume":"44","year":"2022","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B6","volume-title":"Guidelines for the Diagnosis and Treatment of Breast Cancer","year":"2022"},{"key":"B7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0","year":"2017"},{"key":"B9","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30127-X","article-title":"Changing cancer survival in China during 2003\u201315: A pooled analysis of 17 population-based cancer registries","volume":"6","author":"Zeng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100799","article-title":"Survival differences between the USA and an urban population from China for all cancer types and 20 individual cancers: A population-based study","volume":"37","author":"Fu","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02720-x","article-title":"A six-step quality-improvement model for cancer diagnosis and treatment in China","volume":"30","author":"Yang","year":"2024","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(21)00157-2","article-title":"Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study","volume":"12","author":"Zeng","year":"2021","journal-title":"Lancet Public Health"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17223612","article-title":"Delay in diagnosis and treatment of breast cancer: regional disparities","volume":"17","author":"Lima","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.7.683","article-title":"Experts weigh in on promotion, prescription of off-label drugs","volume":"297","author":"Hampton","year":"2007","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105847","article-title":"Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer","volume":"10","author":"Antonarelli","year":"2025","journal-title":"ESMO Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1622854","article-title":"Efficacy and safety of biosimilar trastuzumab (HLX02) in patients with HER2-positive advanced breast cancer: a retrospective real-world analysis","volume":"15","author":"Ye","year":"2025","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1374549","article-title":"Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101444","article-title":"Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients","volume":"5","author":"Liu","year":"2024","journal-title":"Cell Rep Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12507","article-title":"Off-label drug use in oncology: a systematic review of literature","volume":"42","author":"Saiyed","year":"2017","journal-title":"J Clin Pharm Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s40064-015-0981-z","article-title":"Off-label use of cancer therapies in women diagnosed with breast cancer in the United States","volume":"4","author":"Hamel","year":"2015","journal-title":"Springerplus"},{"key":"B22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.6004\/jnccn.2016.0007","article-title":"Prevalence and safety of off-label use of chemotherapeutic agents in older patients with breast cancer: estimates from SEER-Medicare data","volume":"14","author":"Eaton","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl (CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-30-39","article-title":"A multicenter prospective phase II randomized trial of epirubicin\/vinorelbine versus pegylated liposomal doxorubicin\/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study","volume":"30","author":"Vici","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.10.011","article-title":"Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer","volume":"160","author":"Schneeweiss","year":"2022","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.573","article-title":"Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344)","volume":"37","author":"Pohl-Rescigno","year":"2019","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1186\/s12885-021-09050-6","article-title":"Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: A real-world study","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1233-1","article-title":"Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): An open-label, single-group, multicenter, phase 2 trial","volume":"17","author":"Gavil\u00e1","year":"2019","journal-title":"BMC Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3062","article-title":"Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: A systematic review and network meta-analysis","volume":"1","author":"Fujii","year":"2015","journal-title":"JAMA Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-015-0439-8","article-title":"Progress in adjuvant chemotherapy for breast cancer: An overview","volume":"13","author":"Anampa","year":"2015","journal-title":"BMC Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/ajco.12771","article-title":"Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: A multicenter retrospective case\u2013control study","volume":"14","author":"Yang","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.746114","article-title":"Pegylated liposomal doxorubicin versus epirubicin as adjuvant therapy for stage I\u2013III breast cancer","volume":"12","author":"Hu","year":"2021","journal-title":"Front Genet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10549-015-3415-2","article-title":"Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: Results of the phase II CAPRICE study","volume":"151","author":"Gil-Gil","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5013","article-title":"Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study","volume":"27","author":"Sparano","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1597546\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:12:41Z","timestamp":1771924361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1597546\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":34,"alternative-id":["10.3389\/fonc.2026.1597546"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1597546","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"article-number":"1597546"}}